In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT1-like receptor agonist. Response rates after 20–30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials.
DoenickeA, BrandJ, PerrinVL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine attacks.Lancet1988; 1: 1309–11
2.
PerrinVL, FärkkiläM, GoasguenJ, DoenickeA, BrandJ, Tfelt-HansenP. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine.Cephalalgia1989 (this volume)
3.
FowlerPA, ThomasM, LaceyLF, AndrewP, DallasFAA. Early studies with the novel 5-HT1-like agonist GR43175 in healthy volunteers.Cephalalgia1989 (this volume)
4.
Ad Hoc Committee on Classification of Headache of the NIH.JAMA1962; 197: 717–18
